Does additional antimicrobial treatment have a better effect on URTI cough resolution than homeopathic symptomatic therapy alone? A real-life preliminary observational study in a pediatric population by Alessandro Zanasi et al.
Zanasi et al. Multidisciplinary Respiratory Medicine  (2015) 10:25 
DOI 10.1186/s40248-015-0022-3ORIGINAL RESEARCH ARTICLE Open AccessDoes additional antimicrobial treatment
have a better effect on URTI cough resolution
than homeopathic symptomatic therapy alone?
A real-life preliminary observational study in a
pediatric population
Alessandro Zanasi1*, Salvatore Cazzato2, Massimiliano Mazzolini3, Carla Maria Sofia Ierna3, Marianna Mastroroberto4,
Elena Nardi4 and Antonio Maria Morselli-Labate4Abstract
Background: The effectiveness of a homeopathic syrup on cough has been demonstrated in an adult population
in a previous double-blind randomized study. The present prospective observational study investigated children
affected by wet acute cough caused by non-complicated URTIs, comparing those who received the homeopathic
syrup versus those treated with the homeopathic syrup plus antibiotic.
Objectives: The aims were: 1) to assess whether the addition of antibiotics to a symptomatic treatment had a role
in reducing the severity and duration of acute cough in a pediatric population, as well as in improving cough
resolution; 2) to verify the safety of the two treatments.
Methods: Eighty-five children were enrolled in an open study: 46 children received homeopathic syrup alone for
10 days and 39 children received homeopathic syrup for 10 days plus oral antibiotic treatment (amoxicillin/clavulanate,
clarithromycin, and erythromycin) for 7 days. To assess cough severity we used a subjective verbal category-
descriptive (VCD) scale.
Results: Cough VCD score was significantly (P < 0.001) reduced in both groups starting from the second day of
treatment (−0.52 ± 0.66 in the homeopathic syrup group and −0.56 ± 0.55 in children receiving homeopathic
syrup plus oral antibiotic treatment). No significant differences in cough severity or resolution were found
between the two groups of children in any of the 28 days of the study. After the first week (day 8) cough was
completely resolved in more than one-half of patients in both groups. Two children (4.3 %) reported adverse
effects in the group treated with the homeopathic syrup alone, versus 9 children (23.1 %) in the group treated
with the homeopathic syrup plus antibiotics (P = 0.020).
Conclusions: Our data confirm that the homeopathic treatment in question has potential benefits for cough in
children as well, and highlight the strong safety profile of this treatment. Additional antibiotic prescription was
not associated with a greater cough reduction, and presented more adverse events than the homeopathic
syrup alone.
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Acute cough is a very common problem for children;
the majority of them have up to five viral upper re-
spiratory tract infections (URTIs) with cough every
year [1], usually self-limiting within 3 weeks [2, 3].
Generally, such frequency of cough is more applic-
able to young children than to childhood and adoles-
cence [2, 3]. Acute cough in children may last over
20 days and become worrying for the young patients
and their parents [4–6]. Symptomatic treatment is
often prescribed after a medical consultation, al-
though its effectiveness it is still a matter of debate
[7–9], and - contrary to recommendations - antibiotics
are frequently administered to children with acute per-
sistent cough [10–13].
A survey in the United States found that antibiotics
were prescribed to 44 % of patients with common cold,
to 46 % with upper respiratory tract infections and to
75 % with bronchitis. Children aged 0 to four years re-
ceived 53 % of all antibiotics prescribed to the pediatric
population [14].
A Cochrane review of antibiotic use for cough and
common cold concluded that there was not enough evi-
dence of important benefits in the treatment of URTI,
whereas there was a significant increase in adverse
effects associated with antibiotic use [15].
However, parents are rarely satisfied with in the watch-
ful approach, and often have an expectation that antibi-
otics should be prescribed [16]. The aim of this
preliminary study was to evaluate if the addition of anti-
biotics to a symptomatic treatment (homeopathic syrup)
improves cough resolution in pediatric patients with
acute cough due to uncomplicated URTI.
Methods
We conducted an open prospective analysis of acute
cough visits in four ambulatory settings of pediatric
practitioners over a one-year period from December
2013 to December 2014. The study considered only pa-
tients affected by wet acute cough caused by non-
complicated URTIs who either received a homeopathic
syrup alone (Stodal® 200 mL, Boiron SA, Messimy,
France) or were treated with the same homeopathic
syrup plus antibiotic. The homeopathic syrup was com-
posed of: Anemone pulsatilla 6 CH, Rumex crispus 6
CH, Bryonia dioica 3 CH, Ipecacuanha 3 CH, Spongia
tosta 3 CH, Sticta pulmonaria 3 CH, Antimonium tartar-
icum 6 CH, Myocarde 6 CH, Coccus cacti 3 CH,
Drosera MT. The effectiveness of this homeopathic
syrup on cough was investigated in our previous double-
blind randomized study [17]. The syrup’s dosage was
5 mL 4 times per day. Choices of antibiotic use, as well
as antibiotic type and dosage, were left to the discretion
of the physician for each individual patient.Endpoints
The first endpoint was to assess whether the addition of
antibiotics to a symptomatic treatment had a role in re-
ducing the severity and duration of acute cough in a
pediatric population, as well as in improving cough reso-
lution. The second goal was to verify the safety of the
two treatments.
Experimental design
Study assessment was carried out through an analysis of
medical records (including patients’ history, clinical
examination and therapy). All participants filled in a
validated standardized pediatric cough diary (verbal
category-descriptive scale: VCD) to grade the severity of
their cough [18]. The VCD was compiled daily by the
patients, assisted by their parents, for 28 consecutive
days starting from the first visit. This cough-scoring
diary had been previously validated against an objective
cough meter measure, and changes in this subjective
cough rating were shown to reflect changes in cough
counts [18]. The VCD score we used consisted of 6
discrete values: 0 – no cough; 1 – one short period of
mild cough without hardship; 2 – some short periods of
cough without much hardship; 3 – frequent coughing
that does not affect normal daily life or sleep; 4 – serious
coughing that is very frequent and interferes with
normal daily life or sleep; 5 – distressing continuous
coughing that did not stop for 24 h. Cough was con-
sidered resolved when a score of less than 2 was
reached.
Patients were re-examined at the end of the study and
any adverse events were also reported.
Patients
Eighty-five children were found eligible to be enrolled in
the study. Forty-six patients received homeopathic syrup
alone for 10 days (Group 1) and thirty-nine children re-
ceived homeopathic syrup for 10 days plus oral anti-
biotic treatment (amoxicillin/clavulanate, clarithromycin,
and erythromycin) for 7 days (Group 2).
The inclusion criteria were: age between 4 and
15 years, and cough induced by URTIs lasting 5 days or
less. Children with pre-existing respiratory problems
and/or who had antibiotic treatment or any other medi-
cation that might affect the cough symptom within
5 days were excluded from the study.
The baseline characteristics of the two studied groups
are shown in Table 1. The two groups proved compar-
able with respect to sex, age and time from onset of
cough. No significant differences in baseline severity of
cough were found between male and female patients
both in the overall population (P = 0.366) and within the
two groups (P = 0.719 in Group 1 and P = 0.322 in
Group 2).
Table 1 Characteristics of the studied children affected by wet
acute cough caused by non-complicated URTI. Data are shown
as frequencies or mean ± standard deviation
Group 1: Homeopathic
syrup alone (n = 46)
Group 2: Homeopathic
syrup plus antibiotic
treatment (n = 39)
P value
Gender: 0.830a
Male 20 (43.5 %) 18 (46.2 %)
Female 26 (56.5 %) 21 (53.8 %)
Age (years) 8.2 ± 2.9 8.5 ± 2.9 0.674b
Time from the onset
of cough (days)




3.96 ± 0.73 4.00 ± 0.65 0.763b
aFisher’s exact test
bKruskal-Wallis test
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The research was promoted by the Italian Association
for Cough Study (AIST) and was conducted according
to the Helsinki declaration. The protocol was approved
by the Institutional Review Board and the informed
consent was obtained by the legal guardians of the en-
rolled children.Fig. 1 Behavior of verbal category-descriptive (VCD) scale of cough during
cough caused by non-complicated URTI. Data are shown as mean ± standaSample size and power analysis
To evaluate sample size, we hypothesized–for this study
performed on children–the same results obtained previ-
ously in adults after 7 days of administering the same
homeopathic syrup [17] (i.e., a difference between groups
of VCD equal to 0.7 and a within-group standard deviation
of 1.0). Based on these values, we needed to study a total
of at least 76 subjects (i.e., 38 subjects in each group, hy-
pothesizing an equal distribution of patients among the
two groups) to be able to reject the null hypothesis with
probability (power) equal to 0.90 at a significance level of
0.05. The sample size was estimated by means of the “PS
Power and Sample Size Calculations” software (Version
3.0.43; Department of Statistics of the Vanderbilt University,
Nashville, TN, USA; http://biostat.mc.vanderbilt.edu/wiki/
Main/PowerSampleSize) according to the Dupont and
Plummer procedure [19, 20].
Statistical analysis
Frequencies and mean values ± standard deviation were
used as descriptive statistics. The two groups of children
were compared by means of the Fisher’s exact and the
Kruskal-Wallis tests, while the Wilcoxon matched-pairs
signed-rank test was used to test the changes of the VCDthe whole observational period in children affected by wet acute
rd deviation and the Kruskal-Wallis test was applied
Table 2 Improvement of cough during the whole observational
period in children affected by wet acute cough caused by
non-complicated URTI
Day from the start
of treatment
Group 1: Homeopathic
syrup alone (n = 46)
Group 2: Homeopathic
syrup plus antibiotic
treatment (n = 39)
P valuea
2 −0.52 ± 0.66 −0.56 ± 0.55 0.673
3 −1.02 ± 0.75 −0.97 ± 0.74 0.830
4 −1.50 ± 0.84 −1.51 ± 0.68 0.833
5 −1.93 ± 0.88 −1.92 ± 0.96 0.881
6 −2.22 ± 0.99 −2.23 ± 1.01 0.814
7 −2.46 ± 0.98 −2.41 ± 1.29 0.839
8 −2.65 ± 0.87 −2.62 ± 1.09 0.837
9 −2.76 ± 0.87 −2.79 ± 1.03 0.850
10 −2.87 ± 0.88 −2.79 ± 1.00 0.723
11 −2.83 ± 1.00 −2.82 ± 1.00 0.888
12 −2.85 ± 0.99 −2.90 ± 0.94 0.880
13 −2.91 ± 0.96 −3.00 ± 0.92 0.826
14 −3.11 ± 0.99 −3.10 ± 0.99 0.945
15 −3.20 ± 1.02 −3.15 ± 1.01 0.842
16 −3.17 ± 1.10 −3.26 ± 0.99 0.725
17 −3.26 ± 1.08 −3.26 ± 0.94 0.911
18 −3.24 ± 1.06 −3.28 ± 0.86 0.911
19 −3.37 ± 1.02 −3.33 ± 0.90 0.739
20 −3.35 ± 1.04 −3.36 ± 0.90 0.993
21 −3.43 ± 1.00 −3.36 ± 0.90 0.737
22 −3.46 ± 1.00 −3.41 ± 0.91 0.867
23 −3.48 ± 1.03 −3.38 ± 0.96 0.649
24 −3.52 ± 0.98 −3.44 ± 0.94 0.675
25 −3.52 ± 0.98 −3.49 ± 0.91 0.866
26 −3.52 ± 0.98 −3.49 ± 0.91 0.866
27 −3.46 ± 1.00 −3.46 ± 0.94 0.930
28 −3.43 ± 1.03 −3.46 ± 0.94 0.867
The mean (± standard deviation) values of the reported changes in the verbal
category-descriptive (VCD) scale versus the basal ones (Day 1) are shown. All
changes in both groups were highly significant (P < 0.001; Wilcoxon matched-pairs
signed-rank test)
aKruskal-Wallis test
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Statistics package (Version 21; IBM Co., Armonk, NY,
USA) was used to analyze the data. Two-tailed P values
less than 0.05 were considered statistically significant.
Results
Cough severity
Figure 1 shows the behavior of the verbal category-
descriptive (VCD) scale of cough during the entire
observational period. Cough severity was comparable be-
tween the two groups at baseline (Day 1; P = 0.763) as
well as on all other days of the study. We found a highly
significant (P < 0.001) improvement in cough during the
whole observational period from day 2 to day 28, both
in children treated with syrup alone and in those treated
with syrup plus antibiotics, with a non-significant differ-
ence in progressive reduction of cough severity between
the two groups (Table 2).
Cough resolution
The analysis of patients presenting cough (i.e., VCD
score greater than 1) on each day of the study is re-
ported in Fig. 2. Cough resolution began on Day 4
(8.7 % in Group 1 and 5.1 % in Group 2) and continued
progressively through the entire study period. In particu-
lar, after the first week (Day 8) cough was completely re-
solved in more than one-half of patients in both groups
(58.7 % in Group 1 and 53.8 % in Group 2), while 22 %
of patients in Group 1 and 17.9 % of patients in Group 2
were still coughing at Day 21. Cough was still reported
in 8 patients of Group 1 (17.4 %) and in 5 patients of
Group 2 (12.8 %) at the end of the observation, although
the cough in those patients did not interfere with daily
activities and sleep (i.e., VCD score equal to 2 or 3).
Safety
We observed a total of 11 adverse events with a signifi-
cantly (P = 0.020) higher frequency in patients who re-
ceived syrup plus antibiotic treatment than in those who
took syrup alone. In fact, two patients in Group 1
(4.3 %) reported insomnia (n = 1) and vomit (n = 1) while
nine patients in Group 2 (23.1 %) reported diarrhea (n = 4),
vomit (n = 3) and skin rash (n = 2).
Discussion
Our group recently published a controlled randomized
trial demonstrating the favorable effect of a homeopathic
syrup on the resolution of acute cough in adults com-
pared to placebo. [17]. Our data suggest an antitussive
efficacy of this homeopathic syrup in children since the
time-courses of the VCD severity score in the syrup treated
children of this study resulted overlapping to that obtained
in syrup treated adults in a randomized, double-blind
placebo-controlled trail [17]. In fact, after 4 days the meanVCD score was a bit more than 2 both in children (present
study) and in adults [17] versus a mean VDC score of more
than 3 observed in adults treated with placebo [17].
The data of the present study also indicate that adding
antimicrobial agents to the homeopathic syrup does not
in any way benefit the symptomatic treatment–so adding
to the weight of evidence against prescribing antibiotics
to patients with acute cough due to uncomplicated
URTI. The differences in VCD scale between the
homeopathic syrup group and the group that also re-
ceived antibiotics are not statistically significant on any
observation day, and the cough resolution trend was
comparable week after week for both groups (Table 2).
Fig. 2 Cough resolution during the whole observational period in children affected by wet acute cough caused by non-complicated URTI. The
Fisher’s exact test was applied
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was resolved in 74 % of children treated with syrup
alone and in 72 % of children who received syrup plus
antibiotic, while at the end of the 28-day observation
period about 10–20 % of children still presented cough,
without any significant difference between the two treat-
ment groups. These data are consistent with a recent
review on the duration of symptoms of respiratory tract
infections in children [3]. The percentage of children
still presenting cough at the end of the study confirms
that acute cough associated with URTI continues for
several weeks, thus suggesting that it is necessary to
educate people and the medical community about this
natural history.
For the assessment of cough severity we did not
use a complete parent-compiled quality of life quality
(PC-QoL) questionnaire but instead we adopted a subject-
ive verbal category-descriptive (VCD) scale [18]. Although
this scale was validated against an objective cough meter
measure in children slightly older (6–17 year-old) than
our population (4–15 year-old), it can be considered reli-
able also for our study since it is a parent-assisted card.
The VCD was found to be easier to use than the PC-QoL
and so assures better compliance; in fact, we have made apreliminary test on the correct compilation of the VCD
scale and the PC-QoL questionnaire, conducted on 20 pa-
tients for 28 consecutive days, and we obtained a compli-
ance of 95 % for VCD but just 35 % for PC-QoL. It should
also be pointed out that VCD has been proven to have a
high correlation with domain variations of the PC-QoL
questionnaire in children [21, 22]. Furthermore, since the
VCD scale was used in our previous study on the same
homeopathic syrup in adults, applying the same validated
assessment tool in this study on a child population en-
abled us to obtain standardized and comparable data be-
tween children and adults [17].
As far as safety is concerned, it is worth noting that a
significant difference was found between the two groups
of children: only two children in the group treated with
syrup alone reported adverse effects, versus nine children
in the group treated with the syrup plus antibiotics.
As far as the limitations of the research are concerned,
a major weakness of our study arises from the observa-
tional design that we applied in this appraisal. Thus we
did not considered a placebo group since the main goal
of our research was not the effectiveness of homeopatic
syrup but it was to evaluate the role of additional anti-
biotic. It should be pointed out that this research was a
Zanasi et al. Multidisciplinary Respiratory Medicine  (2015) 10:25 Page 6 of 6pilot study conducted before starting a larger trial on the
role of antitussive and mucolytic drugs in children; how-
ever, the results of this preliminary study can provide
valuable information for the sizing of future rigorous
controlled studies, to be planned with a random alloca-
tion of patients to study groups.
Conclusion
In conclusion, our data confirm that the studied homeo-
pathic treatment has potential benefits on cough in chil-
dren, as well as highlighting the good safety profile of
this treatment. Supplementing the syrup with antibiotics
did not improve cough resolution and was associated
with more adverse events than the homeopathic syrup
alone. These results indicate that antibiotics should not
be routinely prescribed for uncomplicated acute cough
secondary to URTI, as they are inappropriate for this
condition and might be even dangerous– leading to
increased antimicrobial resistances and adverse events,
without evidence of benefit [23–27].
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